Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

X4 Pharmaceuticals (XFOR) Cash from Operations (2018 - 2025)

Historic Cash from Operations for X4 Pharmaceuticals (XFOR) over the last 8 years, with Q3 2025 value amounting to -$27.8 million.

  • X4 Pharmaceuticals' Cash from Operations rose 1831.22% to -$27.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.1 million, marking a year-over-year increase of 3527.27%. This contributed to the annual value of -$130.9 million for FY2024, which is 3563.18% down from last year.
  • According to the latest figures from Q3 2025, X4 Pharmaceuticals' Cash from Operations is -$27.8 million, which was up 1831.22% from -$29.9 million recorded in Q2 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Cash from Operations peaked at -$12.4 million during Q1 2025, and registered a low of -$68.8 million during Q3 2023.
  • Over the past 5 years, X4 Pharmaceuticals' median Cash from Operations value was -$26.5 million (recorded in 2023), while the average stood at -$29.1 million.
  • Its Cash from Operations has fluctuated over the past 5 years, first crashed by 25636.59% in 2023, then surged by 6309.19% in 2025.
  • Over the past 5 years, X4 Pharmaceuticals' Cash from Operations (Quarter) stood at -$19.1 million in 2021, then decreased by 0.21% to -$19.1 million in 2022, then plummeted by 45.33% to -$27.7 million in 2023, then decreased by 18.91% to -$33.0 million in 2024, then increased by 15.74% to -$27.8 million in 2025.
  • Its last three reported values are -$27.8 million in Q3 2025, -$29.9 million for Q2 2025, and -$12.4 million during Q1 2025.